Qazi Corner Articles

Patients who underwent ERCP ≤ 30 days post-transplant had greater rates of early post-procedure bleeding but similar rates of technical and clinical success compared to late ERCP.

Findings suggest a heterogeneous makeup of seronegative enteropathies, presenting difficulty in diagnosing patients with villous atrophy and negative celiac serologic testing.

The third quarterly issue of 2024 reviews early versus late ERCP outcomes post-transplant, the impact of GLP-1RA use on endoscopic management, and the differential diagnosis of seronegative villous atrophy.

The second quarterly issue of 2024 reviews outcomes in liver disease after bariatric surgery, glucagon’s role in esophageal impaction management, and outcomes after cuffitis following pouch creation.

Findings suggest cuffitis after ileal pouch-anal anastomosis is linked to long-term complications including strictures and fistulas, potentially contributing to a greater risk of pouch failure.

Findings from a recent randomized controlled trial suggest glucagon does not improve EFBI resolution, time of endoscopy, or extraction length.

The retrospective analysis highlights improved outcomes among patients with obesity and a history of bariatric surgery hospitalized with decompensated cirrhosis.

The first quarterly issue of 2024 reviews a promising JAK inhibitor for acute severe ulcerative colitis, fenofibrates in PBC, new recommendations from the AGA, and a next generation multi-target DNA stool test for detecting colorectal cancer.

Recent recommendations from the AGA may help gastroenterologists manage the rising rate of pouchitis with the aid of clinical evidence.

Findings from a novel study supports the JAK inhibitor tofacitinib as a potential first-line therapy for ASUC.

As clinicians work to improve CRC screening rates, a promising new test has shown favorable accuracy in detecting cases.

The final quarterly issue of the year touches on head-to-head trial data, a new treatment for erosive esophagitis, an ulcerative colitis agent, and the latest ACG recommendations for Celiac disease.e.

An expert reviews the updated recommendations of the American College of Gastroenterology guidelines on the evaluation and management of celiac disease.

While more studies are needed to ensure the safety of long-term therapy with PCABs, this study establishes a role for the use of vonoprazan in the healing and maintenance of healing in patients with erosive esophagitis.

Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.

The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.

This quarter's issue highlights expert perspective on systemic and invasive care for gastric disease, the ELEVATE model, and fecal immunochemical testing for colorectal cancer.

A history of bariatric surgery was associated with up to 50% reduced risk of PDAC among a national cohort.

How an outpatient-based smoking cessation model may come to aid other health systems' gastroenterology patients.

Investigators assess the detection rate of FIT and FIT-DNA among average-risk colorectal cancer screening individuals.

The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.

From new ACG GERD guidelines to the efficacy of colonoscopies, our latest issue addresses topics changing practice and stirring conversation.

A review of changes to clinical, dietary and screening strategies for patients with GERD.

A northern Europe-based trial highlights the potential impact of streamlined and community-supported colonoscopy screening for cancer.

A recent randomized controlled trial showed the limitations of either option, despite being a cornerstone of care.

Analysis from a multicenter, randomized, double-blind, parallel group study comparing the drugs as induction and maintenance therapies in biologic-naïve patients.

The inhibition of Janus kinase to prevent downstream signaling of proinflammatory cytokines has been shown to be a novel method of treating ulcerative colitis.

Risankizumab represents the first ever IL-23 treatment for adult patients with Crohn's disease approved by the FDA.